- Home
- MBRX vs TCBP Comparison
MBRX vs TCBP Comparison
Compare MBRX & TCBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- TCBP
- Stock Information
- Founded
- MBRX 2015
- TCBP 2013
- Country
- MBRX United States
- TCBP United Kingdom
- Employees
- MBRX N/A
- TCBP N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MBRX Health Care
- TCBP Health Care
- Exchange
- MBRX Nasdaq
- TCBP Nasdaq
- Market Cap
- MBRX 1.4M
- TCBP 1.3M
- IPO Year
- MBRX 2016
- TCBP 2022
- Fundamental
- Price
- MBRX $1.28
- TCBP $2.50
- Analyst Decision
- MBRX Strong Buy
- TCBP Strong Buy
- Analyst Count
- MBRX 2
- TCBP 1
- Target Price
- MBRX $24.00
- TCBP $48.00
- AVG Volume (30 Days)
- MBRX 13.3M
- TCBP 473.7K
- Earning Date
- MBRX 03-21-2025
- TCBP 11-25-2024
- Dividend Yield
- MBRX N/A
- TCBP N/A
- EPS Growth
- MBRX N/A
- TCBP N/A
- EPS
- MBRX N/A
- TCBP N/A
- Revenue
- MBRX N/A
- TCBP N/A
- Revenue This Year
- MBRX N/A
- TCBP N/A
- Revenue Next Year
- MBRX N/A
- TCBP N/A
- P/E Ratio
- MBRX N/A
- TCBP N/A
- Revenue Growth
- MBRX N/A
- TCBP N/A
- 52 Week Low
- MBRX $0.40
- TCBP $2.03
- 52 Week High
- MBRX $6.24
- TCBP $523.20
- Technical
- Relative Strength Index (RSI)
- MBRX 46.92
- TCBP 28.65
- Support Level
- MBRX $1.55
- TCBP $2.03
- Resistance Level
- MBRX $2.22
- TCBP $2.68
- Average True Range (ATR)
- MBRX 0.50
- TCBP 0.90
- MACD
- MBRX 0.08
- TCBP -0.02
- Stochastic Oscillator
- MBRX 27.12
- TCBP 8.79
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.